nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—CYP2D6—breast cancer	0.303	1	CbGaD
Betaxolol—CYP1A2—Anastrozole—breast cancer	0.0812	0.25	CbGbCtD
Betaxolol—CYP1A2—Toremifene—breast cancer	0.0743	0.228	CbGbCtD
Betaxolol—CYP2D6—Idarubicin—breast cancer	0.0507	0.156	CbGbCtD
Betaxolol—CYP1A2—Tamoxifen—breast cancer	0.0271	0.0835	CbGbCtD
Betaxolol—CYP2D6—Vinorelbine—breast cancer	0.0248	0.0762	CbGbCtD
Betaxolol—CYP2D6—Tamoxifen—breast cancer	0.0224	0.0688	CbGbCtD
Betaxolol—CYP1A2—Fluorouracil—breast cancer	0.02	0.0615	CbGbCtD
Betaxolol—CYP2D6—Vinblastine—breast cancer	0.0153	0.0469	CbGbCtD
Betaxolol—CYP2D6—Doxorubicin—breast cancer	0.00938	0.0288	CbGbCtD
Betaxolol—Chlorphenesin—CYP19A1—breast cancer	0.000553	0.123	CrCbGaD
Betaxolol—Chlorphenesin—BCHE—breast cancer	0.000552	0.123	CrCbGaD
Betaxolol—Bisoprolol—CYP2D6—breast cancer	0.000295	0.0658	CrCbGaD
Betaxolol—Acebutolol—CYP2D6—breast cancer	0.000279	0.0623	CrCbGaD
Betaxolol—Oxprenolol—CYP2D6—breast cancer	0.000277	0.0619	CrCbGaD
Betaxolol—Chlorphenesin—CYP3A4—breast cancer	0.00026	0.0579	CrCbGaD
Betaxolol—Chlorphenesin—PTGS2—breast cancer	0.000254	0.0567	CrCbGaD
Betaxolol—Alprenolol—CYP2D6—breast cancer	0.000254	0.0566	CrCbGaD
Betaxolol—Bisoprolol—CYP3A4—breast cancer	0.000253	0.0565	CrCbGaD
Betaxolol—Metoprolol—CYP2D6—breast cancer	0.000236	0.0526	CrCbGaD
Betaxolol—Pindolol—CYP2D6—breast cancer	0.000218	0.0487	CrCbGaD
Betaxolol—Atenolol—ABCB1—breast cancer	0.000216	0.0482	CrCbGaD
Betaxolol—Acebutolol—ABCB1—breast cancer	0.0002	0.0445	CrCbGaD
Betaxolol—Metoprolol—ABCB1—breast cancer	0.000168	0.0376	CrCbGaD
Betaxolol—Propranolol—CYP1A1—breast cancer	0.00016	0.0357	CrCbGaD
Betaxolol—Propranolol—CYP2D6—breast cancer	0.000119	0.0266	CrCbGaD
Betaxolol—Propranolol—CYP3A4—breast cancer	0.000102	0.0228	CrCbGaD
Betaxolol—Propranolol—ABCB1—breast cancer	8.5e-05	0.019	CrCbGaD
Betaxolol—Paraesthesia—Docetaxel—breast cancer	4.84e-05	0.000161	CcSEcCtD
Betaxolol—Alopecia—Methotrexate—breast cancer	4.83e-05	0.000161	CcSEcCtD
Betaxolol—Vomiting—Gemcitabine—breast cancer	4.83e-05	0.000161	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—breast cancer	4.82e-05	0.000161	CcSEcCtD
Betaxolol—Dyspnoea—Docetaxel—breast cancer	4.81e-05	0.00016	CcSEcCtD
Betaxolol—Mental disorder—Methotrexate—breast cancer	4.79e-05	0.00016	CcSEcCtD
Betaxolol—Rash—Gemcitabine—breast cancer	4.79e-05	0.00016	CcSEcCtD
Betaxolol—Dermatitis—Gemcitabine—breast cancer	4.79e-05	0.00016	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—breast cancer	4.78e-05	0.00016	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—breast cancer	4.77e-05	0.000159	CcSEcCtD
Betaxolol—Erythema—Methotrexate—breast cancer	4.76e-05	0.000159	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—breast cancer	4.76e-05	0.000159	CcSEcCtD
Betaxolol—Headache—Gemcitabine—breast cancer	4.76e-05	0.000159	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Capecitabine—breast cancer	4.76e-05	0.000159	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—breast cancer	4.75e-05	0.000158	CcSEcCtD
Betaxolol—Flushing—Epirubicin—breast cancer	4.75e-05	0.000158	CcSEcCtD
Betaxolol—Vomiting—Fluorouracil—breast cancer	4.75e-05	0.000158	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—breast cancer	4.75e-05	0.000158	CcSEcCtD
Betaxolol—Dyspepsia—Docetaxel—breast cancer	4.75e-05	0.000158	CcSEcCtD
Betaxolol—Insomnia—Capecitabine—breast cancer	4.72e-05	0.000157	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—breast cancer	4.71e-05	0.000157	CcSEcCtD
Betaxolol—Rash—Fluorouracil—breast cancer	4.71e-05	0.000157	CcSEcCtD
Betaxolol—Dermatitis—Fluorouracil—breast cancer	4.71e-05	0.000157	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—breast cancer	4.7e-05	0.000157	CcSEcCtD
Betaxolol—Paraesthesia—Capecitabine—breast cancer	4.69e-05	0.000156	CcSEcCtD
Betaxolol—Decreased appetite—Docetaxel—breast cancer	4.69e-05	0.000156	CcSEcCtD
Betaxolol—Hypersensitivity—Paclitaxel—breast cancer	4.69e-05	0.000156	CcSEcCtD
Betaxolol—Headache—Fluorouracil—breast cancer	4.68e-05	0.000156	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—breast cancer	4.66e-05	0.000155	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Docetaxel—breast cancer	4.65e-05	0.000155	CcSEcCtD
Betaxolol—Dyspnoea—Capecitabine—breast cancer	4.65e-05	0.000155	CcSEcCtD
Betaxolol—Fatigue—Docetaxel—breast cancer	4.65e-05	0.000155	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—breast cancer	4.64e-05	0.000155	CcSEcCtD
Betaxolol—Nausea—Irinotecan—breast cancer	4.63e-05	0.000154	CcSEcCtD
Betaxolol—Nausea—Mitoxantrone—breast cancer	4.63e-05	0.000154	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—breast cancer	4.62e-05	0.000154	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—breast cancer	4.61e-05	0.000154	CcSEcCtD
Betaxolol—Constipation—Docetaxel—breast cancer	4.61e-05	0.000154	CcSEcCtD
Betaxolol—Pain—Docetaxel—breast cancer	4.61e-05	0.000154	CcSEcCtD
Betaxolol—Dyspepsia—Capecitabine—breast cancer	4.6e-05	0.000153	CcSEcCtD
Betaxolol—Chills—Epirubicin—breast cancer	4.59e-05	0.000153	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—breast cancer	4.57e-05	0.000152	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—breast cancer	4.56e-05	0.000152	CcSEcCtD
Betaxolol—Asthenia—Paclitaxel—breast cancer	4.56e-05	0.000152	CcSEcCtD
Betaxolol—Decreased appetite—Capecitabine—breast cancer	4.54e-05	0.000151	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—breast cancer	4.52e-05	0.000151	CcSEcCtD
Betaxolol—Nausea—Gemcitabine—breast cancer	4.51e-05	0.00015	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Capecitabine—breast cancer	4.51e-05	0.00015	CcSEcCtD
Betaxolol—Fatigue—Capecitabine—breast cancer	4.5e-05	0.00015	CcSEcCtD
Betaxolol—Pruritus—Paclitaxel—breast cancer	4.5e-05	0.00015	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—breast cancer	4.49e-05	0.00015	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—breast cancer	4.48e-05	0.00015	CcSEcCtD
Betaxolol—Pain—Capecitabine—breast cancer	4.46e-05	0.000149	CcSEcCtD
Betaxolol—Constipation—Capecitabine—breast cancer	4.46e-05	0.000149	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—breast cancer	4.46e-05	0.000149	CcSEcCtD
Betaxolol—Erythema—Epirubicin—breast cancer	4.46e-05	0.000149	CcSEcCtD
Betaxolol—Feeling abnormal—Docetaxel—breast cancer	4.44e-05	0.000148	CcSEcCtD
Betaxolol—Nausea—Fluorouracil—breast cancer	4.44e-05	0.000148	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—breast cancer	4.43e-05	0.000148	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—breast cancer	4.42e-05	0.000147	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—breast cancer	4.42e-05	0.000147	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—breast cancer	4.4e-05	0.000147	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—breast cancer	4.4e-05	0.000147	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—breast cancer	4.4e-05	0.000147	CcSEcCtD
Betaxolol—Tension—Epirubicin—breast cancer	4.37e-05	0.000146	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—breast cancer	4.36e-05	0.000146	CcSEcCtD
Betaxolol—Diarrhoea—Paclitaxel—breast cancer	4.35e-05	0.000145	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—breast cancer	4.33e-05	0.000144	CcSEcCtD
Betaxolol—Feeling abnormal—Capecitabine—breast cancer	4.3e-05	0.000143	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—breast cancer	4.3e-05	0.000143	CcSEcCtD
Betaxolol—Malaise—Methotrexate—breast cancer	4.29e-05	0.000143	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—breast cancer	4.28e-05	0.000143	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—breast cancer	4.28e-05	0.000143	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—breast cancer	4.28e-05	0.000143	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—breast cancer	4.27e-05	0.000142	CcSEcCtD
Betaxolol—Body temperature increased—Docetaxel—breast cancer	4.26e-05	0.000142	CcSEcCtD
Betaxolol—Chills—Doxorubicin—breast cancer	4.25e-05	0.000142	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—breast cancer	4.23e-05	0.000141	CcSEcCtD
Betaxolol—Dizziness—Paclitaxel—breast cancer	4.21e-05	0.00014	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—breast cancer	4.2e-05	0.00014	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—breast cancer	4.19e-05	0.00014	CcSEcCtD
Betaxolol—Cough—Methotrexate—breast cancer	4.16e-05	0.000139	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—breast cancer	4.15e-05	0.000138	CcSEcCtD
Betaxolol—Urticaria—Capecitabine—breast cancer	4.15e-05	0.000138	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—breast cancer	4.13e-05	0.000138	CcSEcCtD
Betaxolol—Body temperature increased—Capecitabine—breast cancer	4.13e-05	0.000138	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—breast cancer	4.12e-05	0.000137	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—breast cancer	4.12e-05	0.000137	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—breast cancer	4.12e-05	0.000137	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—breast cancer	4.05e-05	0.000135	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—breast cancer	4.05e-05	0.000135	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—breast cancer	4.05e-05	0.000135	CcSEcCtD
Betaxolol—Tension—Doxorubicin—breast cancer	4.05e-05	0.000135	CcSEcCtD
Betaxolol—Vomiting—Paclitaxel—breast cancer	4.04e-05	0.000135	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—breast cancer	4.04e-05	0.000135	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.03e-05	0.000134	CcSEcCtD
Betaxolol—Malaise—Epirubicin—breast cancer	4.02e-05	0.000134	CcSEcCtD
Betaxolol—Rash—Paclitaxel—breast cancer	4.01e-05	0.000134	CcSEcCtD
Betaxolol—Dermatitis—Paclitaxel—breast cancer	4.01e-05	0.000134	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—breast cancer	4.01e-05	0.000134	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—breast cancer	4e-05	0.000134	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—breast cancer	4e-05	0.000133	CcSEcCtD
Betaxolol—Syncope—Epirubicin—breast cancer	4e-05	0.000133	CcSEcCtD
Betaxolol—Headache—Paclitaxel—breast cancer	3.99e-05	0.000133	CcSEcCtD
Betaxolol—Hypersensitivity—Docetaxel—breast cancer	3.97e-05	0.000132	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—breast cancer	3.96e-05	0.000132	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—breast cancer	3.94e-05	0.000131	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—breast cancer	3.92e-05	0.000131	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—breast cancer	3.92e-05	0.000131	CcSEcCtD
Betaxolol—Cough—Epirubicin—breast cancer	3.89e-05	0.00013	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—breast cancer	3.89e-05	0.00013	CcSEcCtD
Betaxolol—Asthenia—Docetaxel—breast cancer	3.87e-05	0.000129	CcSEcCtD
Betaxolol—Infection—Methotrexate—breast cancer	3.86e-05	0.000129	CcSEcCtD
Betaxolol—Hypersensitivity—Capecitabine—breast cancer	3.85e-05	0.000128	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—breast cancer	3.83e-05	0.000128	CcSEcCtD
Betaxolol—Pruritus—Docetaxel—breast cancer	3.81e-05	0.000127	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—breast cancer	3.81e-05	0.000127	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—breast cancer	3.81e-05	0.000127	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—breast cancer	3.8e-05	0.000127	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—breast cancer	3.79e-05	0.000126	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—breast cancer	3.79e-05	0.000126	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—breast cancer	3.79e-05	0.000126	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—breast cancer	3.78e-05	0.000126	CcSEcCtD
Betaxolol—Nausea—Paclitaxel—breast cancer	3.78e-05	0.000126	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—breast cancer	3.77e-05	0.000126	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.77e-05	0.000126	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—breast cancer	3.76e-05	0.000125	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—breast cancer	3.75e-05	0.000125	CcSEcCtD
Betaxolol—Asthenia—Capecitabine—breast cancer	3.75e-05	0.000125	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—breast cancer	3.72e-05	0.000124	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—breast cancer	3.71e-05	0.000124	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—breast cancer	3.7e-05	0.000124	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—breast cancer	3.7e-05	0.000124	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—breast cancer	3.7e-05	0.000123	CcSEcCtD
Betaxolol—Pruritus—Capecitabine—breast cancer	3.69e-05	0.000123	CcSEcCtD
Betaxolol—Diarrhoea—Docetaxel—breast cancer	3.69e-05	0.000123	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—breast cancer	3.67e-05	0.000122	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—breast cancer	3.64e-05	0.000121	CcSEcCtD
Betaxolol—Oedema—Epirubicin—breast cancer	3.64e-05	0.000121	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—breast cancer	3.63e-05	0.000121	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—breast cancer	3.62e-05	0.000121	CcSEcCtD
Betaxolol—Infection—Epirubicin—breast cancer	3.61e-05	0.00012	CcSEcCtD
Betaxolol—Cough—Doxorubicin—breast cancer	3.6e-05	0.00012	CcSEcCtD
Betaxolol—Shock—Epirubicin—breast cancer	3.58e-05	0.000119	CcSEcCtD
Betaxolol—Diarrhoea—Capecitabine—breast cancer	3.57e-05	0.000119	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—breast cancer	3.57e-05	0.000119	CcSEcCtD
Betaxolol—Dizziness—Docetaxel—breast cancer	3.57e-05	0.000119	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—breast cancer	3.56e-05	0.000119	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—breast cancer	3.55e-05	0.000118	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—breast cancer	3.54e-05	0.000118	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—breast cancer	3.53e-05	0.000118	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—breast cancer	3.52e-05	0.000117	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—breast cancer	3.51e-05	0.000117	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—breast cancer	3.51e-05	0.000117	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—breast cancer	3.51e-05	0.000117	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—breast cancer	3.51e-05	0.000117	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—breast cancer	3.5e-05	0.000117	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—breast cancer	3.49e-05	0.000116	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.49e-05	0.000116	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—breast cancer	3.47e-05	0.000116	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—breast cancer	3.47e-05	0.000116	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—breast cancer	3.46e-05	0.000116	CcSEcCtD
Betaxolol—Dizziness—Capecitabine—breast cancer	3.45e-05	0.000115	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—breast cancer	3.43e-05	0.000114	CcSEcCtD
Betaxolol—Vomiting—Docetaxel—breast cancer	3.43e-05	0.000114	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—breast cancer	3.42e-05	0.000114	CcSEcCtD
Betaxolol—Rash—Docetaxel—breast cancer	3.4e-05	0.000113	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—breast cancer	3.4e-05	0.000113	CcSEcCtD
Betaxolol—Dermatitis—Docetaxel—breast cancer	3.4e-05	0.000113	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—breast cancer	3.39e-05	0.000113	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—breast cancer	3.38e-05	0.000113	CcSEcCtD
Betaxolol—Headache—Docetaxel—breast cancer	3.38e-05	0.000113	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—breast cancer	3.37e-05	0.000112	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—breast cancer	3.36e-05	0.000112	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—breast cancer	3.35e-05	0.000112	CcSEcCtD
Betaxolol—Infection—Doxorubicin—breast cancer	3.34e-05	0.000111	CcSEcCtD
Betaxolol—Pain—Methotrexate—breast cancer	3.32e-05	0.000111	CcSEcCtD
Betaxolol—Vomiting—Capecitabine—breast cancer	3.32e-05	0.000111	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—breast cancer	3.31e-05	0.00011	CcSEcCtD
Betaxolol—Shock—Doxorubicin—breast cancer	3.31e-05	0.00011	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—breast cancer	3.3e-05	0.00011	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—breast cancer	3.29e-05	0.00011	CcSEcCtD
Betaxolol—Rash—Capecitabine—breast cancer	3.29e-05	0.00011	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—breast cancer	3.29e-05	0.00011	CcSEcCtD
Betaxolol—Dermatitis—Capecitabine—breast cancer	3.29e-05	0.00011	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—breast cancer	3.28e-05	0.00011	CcSEcCtD
Betaxolol—Headache—Capecitabine—breast cancer	3.27e-05	0.000109	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—breast cancer	3.27e-05	0.000109	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—breast cancer	3.27e-05	0.000109	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—breast cancer	3.25e-05	0.000108	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—breast cancer	3.24e-05	0.000108	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—breast cancer	3.21e-05	0.000107	CcSEcCtD
Betaxolol—Nausea—Docetaxel—breast cancer	3.2e-05	0.000107	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—breast cancer	3.2e-05	0.000107	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—breast cancer	3.2e-05	0.000107	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—breast cancer	3.16e-05	0.000105	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—breast cancer	3.14e-05	0.000105	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—breast cancer	3.14e-05	0.000105	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—breast cancer	3.14e-05	0.000105	CcSEcCtD
Betaxolol—Constipation—Epirubicin—breast cancer	3.11e-05	0.000104	CcSEcCtD
Betaxolol—Pain—Epirubicin—breast cancer	3.11e-05	0.000104	CcSEcCtD
Betaxolol—Nausea—Capecitabine—breast cancer	3.1e-05	0.000103	CcSEcCtD
Betaxolol—Urticaria—Methotrexate—breast cancer	3.09e-05	0.000103	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—breast cancer	3.07e-05	0.000102	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.07e-05	0.000102	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—breast cancer	3.04e-05	0.000101	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—breast cancer	3.02e-05	0.000101	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—breast cancer	3e-05	0.0001	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—breast cancer	3e-05	9.99e-05	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—breast cancer	2.96e-05	9.88e-05	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—breast cancer	2.93e-05	9.75e-05	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—breast cancer	2.91e-05	9.69e-05	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—breast cancer	2.9e-05	9.67e-05	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—breast cancer	2.89e-05	9.63e-05	CcSEcCtD
Betaxolol—Pain—Doxorubicin—breast cancer	2.88e-05	9.6e-05	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—breast cancer	2.88e-05	9.6e-05	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—breast cancer	2.87e-05	9.59e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—breast cancer	2.86e-05	9.55e-05	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—breast cancer	2.79e-05	9.3e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—breast cancer	2.77e-05	9.25e-05	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—breast cancer	2.75e-05	9.17e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—breast cancer	2.68e-05	8.93e-05	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—breast cancer	2.67e-05	8.91e-05	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—breast cancer	2.66e-05	8.87e-05	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—breast cancer	2.66e-05	8.87e-05	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—breast cancer	2.61e-05	8.7e-05	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—breast cancer	2.57e-05	8.58e-05	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—breast cancer	2.57e-05	8.57e-05	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—breast cancer	2.49e-05	8.3e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—breast cancer	2.48e-05	8.27e-05	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—breast cancer	2.47e-05	8.24e-05	CcSEcCtD
Betaxolol—Rash—Methotrexate—breast cancer	2.45e-05	8.17e-05	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—breast cancer	2.45e-05	8.16e-05	CcSEcCtD
Betaxolol—Headache—Methotrexate—breast cancer	2.43e-05	8.12e-05	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—breast cancer	2.41e-05	8.05e-05	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—breast cancer	2.4e-05	8.02e-05	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—breast cancer	2.38e-05	7.94e-05	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—breast cancer	2.31e-05	7.71e-05	CcSEcCtD
Betaxolol—Nausea—Methotrexate—breast cancer	2.31e-05	7.7e-05	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—breast cancer	2.3e-05	7.68e-05	CcSEcCtD
Betaxolol—Rash—Epirubicin—breast cancer	2.29e-05	7.65e-05	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—breast cancer	2.29e-05	7.64e-05	CcSEcCtD
Betaxolol—Headache—Epirubicin—breast cancer	2.28e-05	7.6e-05	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—breast cancer	2.23e-05	7.42e-05	CcSEcCtD
Betaxolol—Nausea—Epirubicin—breast cancer	2.16e-05	7.2e-05	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—breast cancer	2.14e-05	7.13e-05	CcSEcCtD
Betaxolol—Rash—Doxorubicin—breast cancer	2.12e-05	7.07e-05	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—breast cancer	2.12e-05	7.07e-05	CcSEcCtD
Betaxolol—Headache—Doxorubicin—breast cancer	2.11e-05	7.03e-05	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—breast cancer	2e-05	6.66e-05	CcSEcCtD
Betaxolol—CYP2D6—Metabolism—SLC2A2—breast cancer	1.09e-05	0.000162	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—RAF1—breast cancer	1.09e-05	0.000162	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HES1—breast cancer	1.09e-05	0.000161	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NRG1—breast cancer	1.09e-05	0.000161	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PLA2G4A—breast cancer	1.08e-05	0.00016	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NCOR1—breast cancer	1.08e-05	0.00016	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—H2AFX—breast cancer	1.08e-05	0.00016	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IL2—breast cancer	1.08e-05	0.00016	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—E2F1—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CSF2—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGF1—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CPT1A—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTR—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ABCG2—breast cancer	1.07e-05	0.000159	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—RAF1—breast cancer	1.07e-05	0.000158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CB—breast cancer	1.07e-05	0.000158	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NRG1—breast cancer	1.06e-05	0.000157	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—H2AFX—breast cancer	1.06e-05	0.000156	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IL2—breast cancer	1.06e-05	0.000156	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HPGDS—breast cancer	1.05e-05	0.000156	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—E2F1—breast cancer	1.05e-05	0.000155	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HBA1—breast cancer	1.05e-05	0.000155	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	1.04e-05	0.000155	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SPP1—breast cancer	1.03e-05	0.000152	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL8—breast cancer	1.03e-05	0.000152	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ACHE—breast cancer	1.02e-05	0.000151	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—breast cancer	1.02e-05	0.000151	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB3—breast cancer	1.02e-05	0.000151	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGFR2—breast cancer	1.02e-05	0.000151	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SPP1—breast cancer	1.01e-05	0.000149	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	1.01e-05	0.000149	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	1e-05	0.000148	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB3—breast cancer	9.98e-06	0.000148	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGFR2—breast cancer	9.96e-06	0.000147	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL2—breast cancer	9.81e-06	0.000145	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—breast cancer	9.77e-06	0.000145	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MED12—breast cancer	9.77e-06	0.000145	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—DPYD—breast cancer	9.77e-06	0.000145	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP17A1—breast cancer	9.66e-06	0.000143	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALDOA—breast cancer	9.62e-06	0.000142	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL2—breast cancer	9.6e-06	0.000142	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—breast cancer	9.56e-06	0.000141	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS1—breast cancer	9.56e-06	0.000141	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ENO1—breast cancer	9.56e-06	0.000141	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGFR1—breast cancer	9.49e-06	0.00014	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HIF1A—breast cancer	9.35e-06	0.000138	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA3—breast cancer	9.34e-06	0.000138	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGFR1—breast cancer	9.28e-06	0.000137	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC2A2—breast cancer	9.27e-06	0.000137	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA2—breast cancer	9.2e-06	0.000136	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	9.18e-06	0.000136	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HIF1A—breast cancer	9.14e-06	0.000135	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—LEP—breast cancer	9.12e-06	0.000135	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCG2—breast cancer	9.09e-06	0.000134	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTR—breast cancer	9.09e-06	0.000134	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CPT1A—breast cancer	9.09e-06	0.000134	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CAV1—breast cancer	9.04e-06	0.000134	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KDR—breast cancer	8.94e-06	0.000132	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—LEP—breast cancer	8.93e-06	0.000132	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—FASN—breast cancer	8.92e-06	0.000132	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HPGDS—breast cancer	8.91e-06	0.000132	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—BCHE—breast cancer	8.89e-06	0.000131	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HBA1—breast cancer	8.85e-06	0.000131	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CAV1—breast cancer	8.84e-06	0.000131	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC5A5—breast cancer	8.78e-06	0.00013	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KDR—breast cancer	8.74e-06	0.000129	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ESR1—breast cancer	8.71e-06	0.000129	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ACHE—breast cancer	8.64e-06	0.000128	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—breast cancer	8.64e-06	0.000128	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FN1—breast cancer	8.61e-06	0.000127	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ESR1—breast cancer	8.52e-06	0.000126	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	8.5e-06	0.000126	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NQO1—breast cancer	8.48e-06	0.000125	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC2A1—breast cancer	8.48e-06	0.000125	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	8.42e-06	0.000125	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FN1—breast cancer	8.42e-06	0.000124	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	8.32e-06	0.000123	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP3A4—breast cancer	8.27e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	8.24e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—APC—breast cancer	8.24e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	8.24e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KIT—breast cancer	8.24e-06	0.000122	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP17A1—breast cancer	8.18e-06	0.000121	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGF—breast cancer	8.14e-06	0.00012	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1B1—breast cancer	8.13e-06	0.00012	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ENO1—breast cancer	8.1e-06	0.00012	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS1—breast cancer	8.1e-06	0.00012	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	8.07e-06	0.000119	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	8.06e-06	0.000119	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—APC—breast cancer	8.06e-06	0.000119	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KIT—breast cancer	8.06e-06	0.000119	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HSP90AA1—breast cancer	7.97e-06	0.000118	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	7.96e-06	0.000118	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGF—breast cancer	7.96e-06	0.000118	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2D6—breast cancer	7.94e-06	0.000117	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	7.89e-06	0.000117	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA2—breast cancer	7.79e-06	0.000115	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA1—breast cancer	7.75e-06	0.000115	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—BRAF—breast cancer	7.74e-06	0.000114	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	7.71e-06	0.000114	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP19A1—breast cancer	7.64e-06	0.000113	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—STK11—breast cancer	7.64e-06	0.000113	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—BRAF—breast cancer	7.57e-06	0.000112	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—FASN—breast cancer	7.56e-06	0.000112	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IGF1—breast cancer	7.54e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT2—breast cancer	7.53e-06	0.000111	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—BCHE—breast cancer	7.53e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—breast cancer	7.5e-06	0.000111	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC5A5—breast cancer	7.44e-06	0.00011	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IGF1—breast cancer	7.38e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT2—breast cancer	7.37e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—breast cancer	7.34e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	7.24e-06	0.000107	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC2A1—breast cancer	7.18e-06	0.000106	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NQO1—breast cancer	7.18e-06	0.000106	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	7.17e-06	0.000106	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	7.16e-06	0.000106	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—COMT—breast cancer	7.1e-06	0.000105	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—breast cancer	7.09e-06	0.000105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	7.08e-06	0.000105	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—breast cancer	7.07e-06	0.000105	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	7.03e-06	0.000104	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	7.01e-06	0.000104	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	7e-06	0.000104	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP3A4—breast cancer	7e-06	0.000104	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HMOX1—breast cancer	6.97e-06	0.000103	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.97e-06	0.000103	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ITPR1—breast cancer	6.96e-06	0.000103	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—breast cancer	6.93e-06	0.000103	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1B1—breast cancer	6.89e-06	0.000102	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOS3—breast cancer	6.84e-06	0.000101	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HSP90AA1—breast cancer	6.75e-06	9.98e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ABCB1—breast cancer	6.69e-06	9.9e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOS3—breast cancer	6.69e-06	9.89e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMS—breast cancer	6.57e-06	9.72e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA1—breast cancer	6.57e-06	9.71e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	6.51e-06	9.63e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOR1—breast cancer	6.5e-06	9.61e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PLA2G4A—breast cancer	6.5e-06	9.61e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—breast cancer	6.5e-06	9.61e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MDM2—breast cancer	6.49e-06	9.59e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—STK11—breast cancer	6.47e-06	9.57e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP19A1—breast cancer	6.47e-06	9.57e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RAF1—breast cancer	6.46e-06	9.56e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RELA—breast cancer	6.43e-06	9.51e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB2—breast cancer	6.39e-06	9.46e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	6.37e-06	9.42e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MDM2—breast cancer	6.34e-06	9.38e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RAF1—breast cancer	6.32e-06	9.35e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MTOR—breast cancer	6.31e-06	9.33e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	6.31e-06	9.33e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RELA—breast cancer	6.29e-06	9.31e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB2—breast cancer	6.25e-06	9.25e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GPX1—breast cancer	6.22e-06	9.2e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	6.17e-06	9.13e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MTOR—breast cancer	6.17e-06	9.13e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1A1—breast cancer	6.16e-06	9.11e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ERCC2—breast cancer	6.11e-06	9.03e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	6.08e-06	8.99e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL8—breast cancer	6.06e-06	8.97e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRAS—breast cancer	6.02e-06	8.91e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—COMT—breast cancer	6.02e-06	8.9e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—breast cancer	5.99e-06	8.86e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL8—breast cancer	5.93e-06	8.77e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	5.92e-06	8.76e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HMOX1—breast cancer	5.91e-06	8.74e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ITPR1—breast cancer	5.89e-06	8.72e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRAS—breast cancer	5.89e-06	8.71e-05	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	5.86e-06	8.66e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CASP3—breast cancer	5.8e-06	8.58e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2—breast cancer	5.8e-06	8.57e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	5.79e-06	8.57e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL6—breast cancer	5.77e-06	8.53e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTHFR—breast cancer	5.74e-06	8.49e-05	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	5.73e-06	8.47e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CASP3—breast cancer	5.68e-06	8.4e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCB1—breast cancer	5.67e-06	8.38e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2—breast cancer	5.67e-06	8.38e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—breast cancer	5.65e-06	8.35e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL6—breast cancer	5.64e-06	8.34e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JUN—breast cancer	5.64e-06	8.34e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	5.59e-06	8.27e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMS—breast cancer	5.57e-06	8.23e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—breast cancer	5.53e-06	8.17e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JUN—breast cancer	5.51e-06	8.15e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—breast cancer	5.5e-06	8.14e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PLA2G4A—breast cancer	5.5e-06	8.14e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOR1—breast cancer	5.5e-06	8.14e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—breast cancer	5.48e-06	8.11e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	5.47e-06	8.09e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	5.47e-06	8.08e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTEN—breast cancer	5.45e-06	8.06e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—breast cancer	5.37e-06	7.93e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	5.35e-06	7.91e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK8—breast cancer	5.33e-06	7.89e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTEN—breast cancer	5.33e-06	7.89e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKT1—breast cancer	5.32e-06	7.87e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CAV1—breast cancer	5.3e-06	7.83e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GPX1—breast cancer	5.27e-06	7.79e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1A1—breast cancer	5.22e-06	7.72e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK8—breast cancer	5.22e-06	7.72e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKT1—breast cancer	5.2e-06	7.69e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ERCC2—breast cancer	5.18e-06	7.65e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SRC—breast cancer	5.06e-06	7.48e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SRC—breast cancer	4.95e-06	7.31e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—breast cancer	4.92e-06	7.28e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT3—breast cancer	4.88e-06	7.21e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTHFR—breast cancer	4.86e-06	7.19e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CG—breast cancer	4.82e-06	7.13e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—breast cancer	4.82e-06	7.12e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT3—breast cancer	4.77e-06	7.05e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK3—breast cancer	4.66e-06	6.89e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK3—breast cancer	4.56e-06	6.74e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—breast cancer	4.53e-06	6.7e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—breast cancer	4.52e-06	6.68e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CAV1—breast cancer	4.49e-06	6.64e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—breast cancer	4.43e-06	6.55e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—breast cancer	4.43e-06	6.55e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—breast cancer	4.42e-06	6.54e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—breast cancer	4.34e-06	6.41e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.29e-06	6.34e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CD—breast cancer	4.24e-06	6.27e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—breast cancer	4.19e-06	6.19e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALB—breast cancer	4.19e-06	6.19e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—breast cancer	4.1e-06	6.06e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CG—breast cancer	4.09e-06	6.04e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NOS3—breast cancer	4e-06	5.92e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	3.85e-06	5.69e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	3.76e-06	5.56e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—breast cancer	3.72e-06	5.5e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CB—breast cancer	3.7e-06	5.47e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS2—breast cancer	3.66e-06	5.42e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—breast cancer	3.64e-06	5.38e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CD—breast cancer	3.59e-06	5.31e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRAS—breast cancer	3.56e-06	5.26e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALB—breast cancer	3.55e-06	5.24e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRAS—breast cancer	3.48e-06	5.15e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6—breast cancer	3.41e-06	5.04e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NOS3—breast cancer	3.39e-06	5.02e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6—breast cancer	3.33e-06	4.93e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTEN—breast cancer	3.19e-06	4.72e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT1—breast cancer	3.14e-06	4.65e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CB—breast cancer	3.13e-06	4.63e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS2—breast cancer	3.1e-06	4.59e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT1—breast cancer	3.07e-06	4.55e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTEN—breast cancer	2.71e-06	4e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—breast cancer	2.25e-06	3.33e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—breast cancer	1.91e-06	2.82e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKT1—breast cancer	1.84e-06	2.72e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKT1—breast cancer	1.56e-06	2.31e-05	CbGpPWpGaD
